Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARWR
HOLDArrowhead Pharmaceuticals, Inc. · Healthcare · United States · $12.1B · Avg Vol: $240M/d
COMPANY DESCRIPTION
Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics to treat diseases lacking adequate treatments, with a pipeline targeting genetic and acquired diseases. Its proprietary TRiM™ platform for targeted RNAi delivery provides a competitive edge in developing novel treatments, attracting significant pharma partnerships. The company is a cutting-edge biotechnology firm specializing in RNAi technology with high-growth potential.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 243.2M | 240.7M | 3.6M | 829.4M | 50.5% | 622.0M | 442.3M | 337.3M | -36.2% |
| EPS | -1.63 | -1.91 | -5.00 | -0.01 | — | -2.19 | -3.08 | -4.56 | — |
| Shares | 106.0M | 107.3M | 124.4M | 135.7M | +28.1% | 140.9M | — | — | — |
| Debt | 81.6M | 115.2M | 510.6M | 366.3M | 65.0% | 1.4B | — | — | — |
| Equity | 398.5M | 271.3M | 185.4M | 466.1M | 5.4% | — | — | — | — |
| Op CF | -136.1M | -153.9M | -462.9M | 179.6M | — | -36.3M | — | — | — |
| Inv CF | -5.4M | -96.2M | -420.1M | -129.3M | — | — | — | — | — |
| Fin CF | 65.2M | 253.1M | 870.5M | 74.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARWR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals, Inc.(you) | $12.1B | 36 | HOLD |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.6B | 36 | HOLD |
| BBIO | BridgeBio Pharma, Inc. | $16.5B | 37 | HOLD |
| APGE | Apogee Therapeutics, Inc. | $10.2B | 41 | HOLD |
| AXSM | Axsome Therapeutics, Inc. | $12.4B | 44 | HOLD |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| IMVT | Immunovant, Inc. | $8.1B | 39 | HOLD |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 29 | SELL |
Peer medians: ROE -25.4% · P/E 27.7x · Gross margin 50.5%